CFDE Data Portal | Search KRT18P59

	Label	Description
	KRT18P59 associations Collection (Entity type)	Associations for KRT18P59_associations
	KRT18P59 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	KRT18P59 Gene (Entity type)	ENSG00000187686 - keratin 18 pseudogene 59
	GSE119978 GSE180930 cisplatin 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 dexamethasone 3 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 XPO1 inhibition Dexamethasone 3 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE128076 doxycycline HEK293 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE215461 topotecan 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	KCNAB3 IDG ionchannel ARCHS4 coexpression Gene Set (Entity type)	A Gene Set from IDG
	GPR157 IDG GPCR ARCHS4 coexpression Gene Set (Entity type)	A Gene Set from IDG

KRT18P59 associations

Associations for KRT18P59_associations

KRT18P59 associations.tsv

A file from IDG as part of the Harmonizome project

KRT18P59

ENSG00000187686 - keratin 18 pseudogene 59

GSE119978 GSE180930 cisplatin 2 v 1 human dn

A Gene Set from LINCS

GSE135350 dexamethasone 3 v 7 human up

A Gene Set from LINCS

GSE135350 XPO1 inhibition Dexamethasone 3 v 7 human up

A Gene Set from LINCS

GSE128076 doxycycline HEK293 1 v 3 human up

A Gene Set from LINCS

GSE215461 topotecan 0 v 1 human up

A Gene Set from LINCS

KCNAB3 IDG ionchannel ARCHS4 coexpression

A Gene Set from IDG

GPR157 IDG GPCR ARCHS4 coexpression

A Gene Set from IDG

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.